{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:46:28Z","timestamp":1785332788556,"version":"3.55.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s40265-013-0099-y","type":"journal-article","created":{"date-parts":[[2013,8,2]],"date-time":"2013-08-02T11:37:18Z","timestamp":1375443438000},"page":"1339-1355","source":"Crossref","is-referenced-by-count":14,"title":["Sumatriptan\/Naproxen Sodium: A Review of Its Use in Adult Patients with Migraine"],"prefix":"10.1007","volume":"73","author":[{"given":"Lily P. H.","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,3]]},"reference":[{"issue":"3","key":"99_CR1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1468-2982.2007.01288.x","volume":"27","author":"L Stovner","year":"2007","unstructured":"Stovner L, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27(3):193\u2013210.","journal-title":"Cephalalgia."},{"issue":"6","key":"99_CR2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10194-005-0252-4","volume":"6","author":"M Leonardi","year":"2005","unstructured":"Leonardi M, Steiner TJ, Scher AT, et al. The global burden of migraine: measuring disability in headache disorders with WHO\u2019s Classification of Functioning, Disability and Health (ICF). J Headache Pain. 2005;6(6):429\u201340.","journal-title":"J Headache Pain"},{"issue":"5","key":"99_CR3","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/11630590-000000000-00000","volume":"26","author":"P Tfelt-Hansen","year":"2012","unstructured":"Tfelt-Hansen P, Olesen J. Taking the negative view of current migraine treatments: the unmet needs. CNS Drugs. 2012;26(5):375\u201382.","journal-title":"CNS Drugs"},{"issue":"3","key":"99_CR4","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1526-4610.2006.00631.x","volume":"47","author":"S Diamond","year":"2007","unstructured":"Diamond S, Bigal ME, Silberstein S, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache. 2007;47(3):355\u201363.","journal-title":"Headache"},{"issue":"5","key":"99_CR5","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343\u20139.","journal-title":"Neurology"},{"issue":"6","key":"99_CR6","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.55.6.754","volume":"55","author":"SD Silberstein","year":"2000","unstructured":"Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology [published erratum appears in Neurology. 2000;56(1):142]. Neurology. 2000;55(6):754\u201362.","journal-title":"Neurology"},{"issue":"10","key":"99_CR7","doi-asserted-by":"crossref","first-page":"840","DOI":"10.7326\/0003-4819-137-10-200211190-00014","volume":"137","author":"V Snow","year":"2002","unstructured":"Snow V, Weiss K, Wall EM, et al. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med. 2002;137(10):840\u20139.","journal-title":"Ann Intern Med"},{"issue":"9","key":"99_CR8","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1468-1331.2009.02748.x","volume":"16","author":"S Evers","year":"2009","unstructured":"Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine: revised report of an EFNS task force. Eur J Neurol. 2009;16(9):968\u201381.","journal-title":"Eur J Neurol"},{"issue":"10","key":"99_CR9","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2165\/11635440-000000000-00000","volume":"26","author":"AN Silva Da","year":"2012","unstructured":"Da Silva AN, Tepper SJ. Acute treatment of migraines. CNS Drugs. 2012;26(10):823\u201339.","journal-title":"CNS Drugs"},{"key":"99_CR10","unstructured":"GlaxoSmithKline. Treximet\u00ae (sumatriptan and naproxen sodium) tablets: US prescribing information. 2012. http:\/\/us.gsk.com\/products\/assets\/us_treximet.pdf . Accessed 5 Dec 2012."},{"issue":"6","key":"99_CR11","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2165\/00003495-200060060-00003","volume":"60","author":"P Tfelt-Hansen","year":"2000","unstructured":"Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000;60(6):1259\u201387.","journal-title":"Drugs"},{"issue":"2","key":"99_CR12","doi-asserted-by":"crossref","first-page":"81s","DOI":"10.18433\/J3T886","volume":"11","author":"P Rao","year":"2008","unstructured":"Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci. 2008;11(2):81s\u2013110s.","journal-title":"J Pharm Pharm Sci"},{"key":"99_CR13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/DDDT.S8410","volume":"4","author":"CK Khoury","year":"2010","unstructured":"Khoury CK, Couch JR. Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal. Drug Des Devel Ther. 2010;4:9\u201317.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"99_CR14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1526-4610.2011.02048.x","volume":"52","author":"CV Vause","year":"2012","unstructured":"Vause CV, Durham PL. Identification of cytokines and signaling proteins differentially regulated by sumatriptan\/naproxen. Headache. 2012;52(1):80\u20139.","journal-title":"Headache"},{"issue":"1 Suppl","key":"99_CR15","first-page":"45","volume":"31","author":"M Felice De","year":"2011","unstructured":"De Felice M, Edelmayer R, Kasasbeh A, et al. Chronic exposure to sumatriptan, but not to sumatriptan plus naproxen, induces latent sensitization and increased excitability of dural afferents [abstract no. PS1-59]. Cephalalgia. 2011;31(1 Suppl):45.","journal-title":"Cephalalgia"},{"key":"99_CR16","doi-asserted-by":"crossref","unstructured":"Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012;2:CD008615.","DOI":"10.1002\/14651858.CD008615.pub2"},{"issue":"5","key":"99_CR17","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/j.1526-4610.2010.01635.x","volume":"50","author":"CC Suthisisang","year":"2012","unstructured":"Suthisisang CC, Poolsup N, Suksomboon N, et al. Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine. Headache. 2012;50(5):808\u201318.","journal-title":"Headache"},{"key":"99_CR18","doi-asserted-by":"crossref","unstructured":"Krymchantowski AV. Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq Neuropsiquiatr. 2000;58(2B):428\u201330.","DOI":"10.1590\/S0004-282X2000000300006"},{"issue":"8","key":"99_CR19","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/j.1526-4610.2005.05178.x","volume":"45","author":"TR Smith","year":"2005","unstructured":"Smith TR, Sunshine A, Stark SR, et al. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2005;45(8):983\u201391.","journal-title":"Headache"},{"issue":"3","key":"99_CR20","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1526-4610.2009.01606.x","volume":"50","author":"LJ Haberer","year":"2010","unstructured":"Haberer LJ, Walls CM, Lener SE, et al. Distinct pharmacokinetic profile and safety of a fixed-dose tablet of sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2010;50(3):357\u201373.","journal-title":"Headache"},{"issue":"12","key":"99_CR21","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1751-7176.2011.00554.x","volume":"13","author":"WB White","year":"2011","unstructured":"White WB, Derosier FJ, Thompson AH, et al. Evaluation of the migraine treatment sumatriptan\/naproxen sodium on blood pressure following long-term administration. J Clin Hypertens. 2011;13(12):910\u20136.","journal-title":"J Clin Hypertens"},{"issue":"4","key":"99_CR22","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/head.12052","volume":"53","author":"KR Edwards","year":"2013","unstructured":"Edwards KR, Rosenthal BL, Farmer KU, et al. Evaluation of sumatriptan-naproxen in the treatment of acute migraine: a placebo-controlled, double-blind, cross-over study assessing cognitive function. Headache. 2013;53(4):656\u201364.","journal-title":"Headache"},{"issue":"1","key":"99_CR23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/00912700022008621","volume":"40","author":"P Srinivasu","year":"2000","unstructured":"Srinivasu P, Rambhau D, Rao BR, et al. Lack of pharmacokinetic interaction between sumatriptan and naproxen. J Clin Pharmacol. 2000;40(1):99\u2013104.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"99_CR24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00003495-199040010-00006","volume":"40","author":"PA Todd","year":"1990","unstructured":"Todd PA, Clissold SP. Naproxen: a reappraisal of its pharmacology, and therapeutic use in rheumatic diseases and pain states. Drugs. 1990;40(1):91\u2013137.","journal-title":"Drugs"},{"issue":"13","key":"99_CR25","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/jama.297.13.1443","volume":"297","author":"JL Brandes","year":"2007","unstructured":"Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007;297(13):1443\u201354.","journal-title":"JAMA"},{"issue":"2","key":"99_CR26","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/01.wnl.0000316800.22949.20","volume":"71","author":"SD Silberstein","year":"2008","unstructured":"Silberstein SD, Mannix LK, Goldstein J, et al. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine [published erratum appears in Neurology. 2009;72(15):1369]. Neurology. 2008;71(2):114\u201321.","journal-title":"Neurology"},{"issue":"1","key":"99_CR27","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/AOG.0b013e3181a98e4d","volume":"114","author":"LK Mannix","year":"2009","unstructured":"Mannix LK, Martin VT, Cady RK, et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Obstet Gynecol. 2009;114(1):106\u201313.","journal-title":"Obstet Gynecol"},{"issue":"8","key":"99_CR28","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1468-2982.2008.01806.x","volume":"29","author":"RB Lipton","year":"2009","unstructured":"Lipton RB, Dodick DW, Adelman JU, et al. Consistency of response to sumatriptan\/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia. 2009;29(8):826\u201336.","journal-title":"Cephalalgia"},{"issue":"7","key":"99_CR29","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1526-4610.2009.01458.x","volume":"49","author":"NT Mathew","year":"2009","unstructured":"Mathew NT, Landy S, Stark S, et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache. 2009;49(7):971\u201382.","journal-title":"Headache"},{"issue":"5","key":"99_CR30","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1526-4610.2007.00790.x","volume":"47","author":"T Smith","year":"2007","unstructured":"Smith T, Blumenthal H, Diamond M, et al. Sumatriptan\/naproxen sodium for migraine: efficacy, health related quality of life, and satisfaction outcomes. Headache. 2007;47(5):683\u201392.","journal-title":"Headache"},{"issue":"6","key":"99_CR31","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1526-4610.2011.01912.x","volume":"51","author":"R Cady","year":"2011","unstructured":"Cady R, Banks J, Nett RB, et al. Multi-center comparison of response to a single tablet of sumatriptan 85\u00a0mg and naproxen 500\u00a0mg vs usual therapy treating multiple migraine attacks as measured by the completeness of response survey. Headache. 2011;51(6):961\u201370.","journal-title":"Headache"},{"issue":"1","key":"99_CR32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1526-4610.2011.01992.x","volume":"52","author":"S Landy","year":"2012","unstructured":"Landy S, Hoagland R, Hoagland NA. Sumatriptan-naproxen migraine efficacy in allodynic patients: early intervention. Headache. 2012;52(1):133\u20139.","journal-title":"Headache"},{"issue":"2","key":"99_CR33","first-page":"53","volume":"9","author":"S Landy","year":"2007","unstructured":"Landy S, DeRossett SE, Rapoport A, et al. Two double-blind, multicenter, randomized, placebo-controlled, single-dose studies of sumatriptan\/naproxen sodium in the acute treatment of migraine: function, productivity, and satisfaction outcomes. MedGenMed. 2007;9(2):53.","journal-title":"MedGenMed"},{"issue":"3","key":"99_CR34","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/1756285609102769","volume":"2","author":"S Landy","year":"2009","unstructured":"Landy S, White J, Lener SE, et al. Fixed-dose sumatriptan\/naproxen sodium compared with each monotherapy utilizing the novel composite endpoint of sustained pain-free\/no adverse events. Ther Adv Neurol Disord. 2009;2(3):135\u201341.","journal-title":"Ther Adv Neurol Disord"},{"key":"99_CR35","unstructured":"Lener S, Richard N, McDonald S, et al. Prior acute treatment of migraine is not a predictive factor of sumatriptan\/naproxen sodium (SumaRT\/Nap) response or superiority over the components [abstract no. PO32]. Cephalalgia. 2009;29(1 Suppl):23\u20134."},{"key":"99_CR36","unstructured":"Derosier F, Thompson AH, Richard N. Exploration of the relationship between presence or absence of aura to response and tolerability after treatment with sumatriptan 85\u00a0mg formulated with RT technology\/naproxen sodium 500\u00a0mg (SumaRT\/Nap) for the early intervention treatment of migraine [abstract no. PO258]. Cephalalgia. 2009;29(1 Suppl):112\u20133."},{"issue":"1 Suppl","key":"99_CR37","first-page":"26","volume":"29","author":"PK Winner","year":"2009","unstructured":"Winner PK, Brandes JL, Thompson AH, et al. Evaluation of the relationship body mass index (BMI) to response and tolerability after treatment with sumatriptan 85\u00a0mg formulated with RT technology\/naproxen sodium 500\u00a0mg (SumaRT\/Nap) for the early intervention treatment of migraine [abstract no. PO38]. Cephalalgia. 2009;29(1 Suppl):26.","journal-title":"Cephalalgia"},{"key":"99_CR38","unstructured":"Lener S, Palchinsky J, Richard N, et al. Does gender affect efficacy and tolerability of SumaRT\/Nap during the early intervention treatment of migraine? [abstract no. P06.247]. In: Proceedings of the 62nd annual meeting of the American Academy of Neurology; 10\u201317 Apr 2010; Toronto."},{"issue":"4","key":"99_CR39","first-page":"195","volume":"14","author":"FR Taylor","year":"2007","unstructured":"Taylor FR, Heiring JO, Messina E, et al. Sumatriptan\/naproxen sodium as early intervention for migraine: effects on functional ability, productivity, and satisfaction in 2 randomized controlled trials. J Clin Outcomes Manage. 2007;14(4):195\u2013204.","journal-title":"J Clin Outcomes Manage"},{"issue":"5","key":"99_CR40","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/j.1526-4610.2011.01894.x","volume":"51","author":"RK Cady","year":"2011","unstructured":"Cady RK, Diamond ML, Diamond MP, et al. Sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache. 2011;51(5):664\u201373.","journal-title":"Headache"},{"issue":"1 Suppl","key":"99_CR41","first-page":"25","volume":"29","author":"RB Lipton","year":"2009","unstructured":"Lipton RB, McDonald SA, Richard NE, et al. Evaluation of consistency of adverse events after treatment of multiple attacks with a fixed-dose single tablet of sumatriptan and naproxen sodium (SumaRT\/Nap) [abstract no. PO35]. Cephalalgia. 2009;29(1 Suppl):25.","journal-title":"Cephalalgia"},{"issue":"1","key":"99_CR42","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0025-6196(11)60968-3","volume":"82","author":"P Winner","year":"2007","unstructured":"Winner P, Cady RK, Ruoff GE, et al. Twelve-month tolerability and safety of sumatriptan-naproxen sodium for the treatment of acute migraine. Mayo Clin Proc. 2007;82(1):61\u20138.","journal-title":"Mayo Clin Proc"},{"issue":"17","key":"99_CR43","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.2165\/11641120-000000000-00000","volume":"72","author":"RJ Cady","year":"2012","unstructured":"Cady RJ, Shade CL, Cady RK. Advances in drug development for acute migraine. Drugs. 2012;72(17):2187\u2013205.","journal-title":"Drugs"},{"issue":"9","key":"99_CR44","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2165\/00023210-200519090-00004","volume":"19","author":"E Loder","year":"2005","unstructured":"Loder E. Fixed drug combinations for the acute treatment of migraine: place in therapy. CNS Drugs. 2005;19(9):769\u201384.","journal-title":"CNS Drugs"},{"key":"99_CR45","doi-asserted-by":"crossref","unstructured":"Straube A, Aicher B, Fiebich BL, et al. Combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics? BMC Neurol. 2011;11:43.","DOI":"10.1186\/1471-2377-11-43"},{"issue":"20","key":"99_CR46","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1001\/jama.284.20.2640","volume":"284","author":"DB Matchar","year":"2000","unstructured":"Matchar DB, McCrory DC, Gray RN. Toward evidence-based management of migraine. JAMA. 2000;284(20):2640\u20131.","journal-title":"JAMA"},{"issue":"20","key":"99_CR47","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1001\/jama.284.20.2599","volume":"284","author":"RB Lipton","year":"2000","unstructured":"Lipton RB, Stewart WF, Stone AM, et al. Stratified care vs step care strategies for migraine: the disability in strategies of care (DISC) study: a randomized trial. JAMA. 2000;284(20):2599\u2013605.","journal-title":"JAMA"},{"issue":"6","key":"99_CR48","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2036.1992.tb00732.x","volume":"6","author":"LA Houghton","year":"1992","unstructured":"Houghton LA, Fowler P, Keene ON, et al. Effect of sumatriptan, a new selective 5HT1-like agonist, on liquid gastric emptying in man. Aliment Pharmacol Ther. 1992;6(6):685\u201391.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"99_CR49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.dld.2003.09.012","volume":"36","author":"E Moro","year":"2004","unstructured":"Moro E, Crema F, De Ponti F, et al. Triptans and gastric accommodation: pharmacological and therapeutic aspects. Dig Liver Dis. 2004;36(1):85\u201392.","journal-title":"Dig Liver Dis"},{"issue":"5","key":"99_CR50","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2165\/00044011-199611050-00006","volume":"11","author":"PU Rani","year":"1996","unstructured":"Rani PU, Naidu MUR, Rao TRK, et al. Sumatriptan delays paracetamol absorption in migraine patients. Clin Drug Invest. 1996;11(5):300\u20134.","journal-title":"Clin Drug Invest"},{"issue":"6","key":"99_CR51","first-page":"702","volume":"27","author":"MC Runken","year":"2007","unstructured":"Runken MC, Landy S, Silberstein S, et al. Impact of early versus late intervention on productivity and clinical disability in migraineurs [abstract no. E045]. Cephalalgia. 2007;27(6):702.","journal-title":"Cephalalgia"},{"key":"99_CR52","unstructured":"GlaxoSmithKline LLC. Imitrex\u00ae (sumatriptan succinate) film-coated tablets: US prescribing information. Mar 2012. http:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=584abe73-8290-4484-ff8e-5890831c095e . Accessed 23 Jan 2013."},{"key":"99_CR53","unstructured":"Teva Pharmaceuticals USA Inc. Naproxen sodium film-coated tablets: US prescribing information. Jul 2012. http:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?id=72853 . Accessed 23 Jan 2013."},{"issue":"5","key":"99_CR54","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1526-4610.2004.04078.x","volume":"44","author":"D Dodick","year":"2004","unstructured":"Dodick D, Lipton RB, Martin V, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004;44(5):414\u201325.","journal-title":"Headache"},{"key":"99_CR55","doi-asserted-by":"crossref","first-page":"c7086","DOI":"10.1136\/bmj.c7086","volume":"342","author":"S Trelle","year":"2011","unstructured":"Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.","journal-title":"BMJ"},{"issue":"12","key":"99_CR56","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1161\/CIRCULATIONAHA.106.181424","volume":"115","author":"EM Antman","year":"2007","unstructured":"Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115(12):1634\u201342.","journal-title":"Circulation"},{"issue":"1","key":"99_CR57","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2165\/00023210-200721010-00006","volume":"21","author":"D Dodick","year":"2007","unstructured":"Dodick D, Sandrini G, Williams P. Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine. CNS Drugs. 2007;21(1):73\u201382.","journal-title":"CNS Drugs"},{"key":"99_CR58","unstructured":"Runken MC, Goodwin B, Shah M, et al. Differences in pharmacotherapy utilization for patients initiating a fixed-dose tablet of sumatriptan and naproxen sodium vs oral triptan therapy in the treatment of acute migraine [abstract no. PO-37]. Headache. 2010;50(Suppl s1):19."},{"key":"99_CR59","unstructured":"GlaxoSmithKline. The combination product of sumatriptan and naproxen sodium pharmacy budget impact model database validation study [study no. 111208]. 12 Sep 2011. http:\/\/www.gsk-clinicalstudyregister.com . Accessed 13 Dec 2012."},{"key":"99_CR60","unstructured":"GlaxoSmithKline. Sumatriptan\/naproxen sodium vs single-entity oral triptans: an analysis of real-world data [study no. 113913]. 9 Apr 2012. http:\/\/www.gsk-clinicalstudyregister.com . Accessed 13 Dec 2012."},{"issue":"1","key":"99_CR61","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2174\/157488412799218770","volume":"7","author":"P Tfelt-Hansen","year":"2012","unstructured":"Tfelt-Hansen P. Clinical pharmacology of current and future drugs for the acute treatment of migraine: a review and an update. Curr Clin Pharmacol. 2012;7(1):66\u201372.","journal-title":"Curr Clin Pharmacol"},{"issue":"4","key":"99_CR62","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.1526-4610.2011.02058.x","volume":"52","author":"A Blumenfeld","year":"2012","unstructured":"Blumenfeld A, Gennings C, Cady R. Pharmacological synergy: the next frontier on therapeutic advancement for migraine. Headache. 2012;52(4):636\u201347.","journal-title":"Headache"},{"issue":"4","key":"99_CR63","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ejpain.2011.08.009","volume":"16","author":"RA Moore","year":"2012","unstructured":"Moore RA, Derry CJ, Derry S, et al. A conservative method of testing whether combination analgesics produce additive or synergistic effects using evidence from acute pain and migraine. Eur J Pain. 2012;16(4):585\u201391.","journal-title":"Eur J Pain"},{"issue":"4","key":"99_CR64","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1526-4610.2011.02039.x","volume":"52","author":"F Derosier","year":"2012","unstructured":"Derosier F, Sheftell F, Silberstein S, et al. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache. 2012;52(4):530\u201343.","journal-title":"Headache"},{"issue":"4","key":"99_CR65","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1526-4610.2012.02115.x","volume":"52","author":"PC Tfelt-Hansen","year":"2012","unstructured":"Tfelt-Hansen PC, Diener HC. Why should American headache and migraine patients still be treated with butalbital-containing medicine? Headache. 2012;52(4):672\u20134.","journal-title":"Headache"},{"issue":"4","key":"99_CR66","first-page":"191","volume":"7","author":"W McLean","year":"2000","unstructured":"McLean W, Boucher EA, Brennan M, et al. Is there an indication for the use of barbiturate-containing analgesic agents in the treatment of pain? Guidelines for their safe use and withdrawal management. Canadian Pharmacists Association. Can J Clin Pharmacol. 2000;7(4):191\u20137.","journal-title":"Can J Clin Pharmacol"},{"issue":"8","key":"99_CR67","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/j.1526-4610.2012.02186.x","volume":"52","author":"L Robbins","year":"2012","unstructured":"Robbins L. In defense of butalbital. Headache. 2012;52(8):1323\u20134.","journal-title":"Headache"},{"issue":"11","key":"99_CR68","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s40263-012-0002-5","volume":"26","author":"PE Rolan","year":"2012","unstructured":"Rolan PE. Drug interactions with triptans: which are clinically significant? CNS Drugs. 2012;26(11):949\u201357.","journal-title":"CNS Drugs"},{"issue":"2","key":"99_CR69","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1526-4610.2011.02067.x","volume":"52","author":"DA Sclar","year":"2012","unstructured":"Sclar DA, Robison LM, Castillo LV, et al. Concomitant use of triptan, and SSRI or SNRI after the US Food and Drug Administration alert on serotonin syndrome. Headache. 2012;52(2):198\u2013203.","journal-title":"Headache"},{"issue":"6","key":"99_CR70","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/j.1526-4610.2010.01691.x","volume":"50","author":"RW Evans","year":"2010","unstructured":"Evans RW, Tepper SJ, Shapiro RE, et al. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper. Headache. 2010;50(6):1089\u201399.","journal-title":"Headache"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0099-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0099-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0099-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T23:13:41Z","timestamp":1715814821000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0099-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":70,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["99"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0099-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}